AI
| Followers | 843 |
| Posts | 122891 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Sunday, February 11, 2007 10:10:08 PM
U.S. Market Share of HBV Drugs
Dew’s notes (from Oct 2006):
1. Hepsera (the black line on the chart) is the current market leader in Rx’s by a wide margin. This is bullish for IDIX because Tyzeka is a much more efficacious drug than Hepsera (#msg-rrrrrrrrr).
2. As new HBV drugs are launched, they expand the overall market rather than just stealing share from older drugs. This can be seen from the steady uptake of total prescriptions (the indigo line on the chart) during the period in which Baraclude and Hepsera were introduced. Despite being the oldest and least efficacious drug in the class, Epivir/Lamivudine (the red line on the chart) has maintained a near-constant number of prescriptions during the past four years.
Dew’s notes (from Oct 2006):
1. Hepsera (the black line on the chart) is the current market leader in Rx’s by a wide margin. This is bullish for IDIX because Tyzeka is a much more efficacious drug than Hepsera (#msg-rrrrrrrrr).
2. As new HBV drugs are launched, they expand the overall market rather than just stealing share from older drugs. This can be seen from the steady uptake of total prescriptions (the indigo line on the chart) during the period in which Baraclude and Hepsera were introduced. Despite being the oldest and least efficacious drug in the class, Epivir/Lamivudine (the red line on the chart) has maintained a near-constant number of prescriptions during the past four years.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
